Synaffix and Sidewinder Agree to Advance Next-Generation Bispecific ADC Development

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), and Sidewinder Therapeutics, a precision ADC therapeutics company, signed a multi-target licensing agreement to develop first-in-class bispecific ADC therapeutics to treat solid tumor indications.

Sidewinder gains access to Lonza’s ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and a toxSYN® linker payload. Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Lonza is responsible for manufacturing components that are related to its proprietary technologies, and Sidewinder is responsible for the research, development, manufacturing, and commercialization of the ADCs.

“This collaboration brings together two cutting-edge platforms to enhance the therapeutic index of bispecific ADCs by minimizing impact on healthy tissue,” said Peter van de Sande, head of Synaffix at Lonza. “We are confident that our technologies will help Sidewinder’s pipeline reach its full potential in maximizing tumor targeting, hence delivering new life-saving therapies for the benefit of patients with cancer.”

“The ADC field has reached an exciting moment fueled by multiple technology breakthroughs that enable the next generation of bispecific ADC innovation, added Eric Murphy, PhD, co‑founder and CEO of Sidewinder Therapeutics.

“Sidewinder’s bispecific antibody approach targeting tumor-specific receptor complexes, combined with Synaffix’s clinically validated site-specific linker-payload platform, creates an ideal synergy with the potential to greatly impact patient benefit. This collaboration advances our mission to reshape the cancer treatment landscape by improving tolerability for bispecific ADCs.”

The post Synaffix and Sidewinder Agree to Advance Next-Generation Bispecific ADC Development appeared first on GEN - Genetic Engineering and Biotechnology News.